3 Beaten-Down Stocks With GLP-1 Exposure To Buy And Hold

The first GLP-1 medicine was approved in the U.S. in 2005 for the treatment of type 2 diabetes. Since then, breakthroughs have occurred in the field. Medicines in this class are now indicated for chronic weight management, obstructive sleep apnea, metabolic dysfunction-associated steatohepatitis, and other conditions.

Analysts predict that the market for GLP-1 drugs will expand rapidly over the next decade, and several companies could capitalize on it. Let's consider three corporations whose businesses may benefit from the GLP-1 boom to invest in today.

This post originally appeared at The Motley Fool.